Back to top

cell-therapy: Archive

Zacks Equity Research

ATRA Stock Down After FDA Issues CRL for Rare Blood Cancer Candidate

Atara stock plunges 41% upon the FDA issuance of a CRL against its BLA for Ebvallo to treat EBV+ PTLD. The company is also facing a severe cash crunch.

BMRNPositive Net Change ATRAPositive Net Change CTMXPositive Net Change CSTLNegative Net Change

Zacks Equity Research

SANA Stock Surges 152% in a Week on Upbeat Initial Diabetes Study Data

Sana stock soars in a week following positive initial data from a first-in-human study of investigational cell therapy, UP421, in diabetes patients.

HALOPositive Net Change CTMXPositive Net Change CSTLNegative Net Change SANAPositive Net Change

Zacks Equity Research

CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA

Capricor stock gains 8% upon completing the rolling submission of the BLA for its lead asset, deramiocel, to treat DMD cardiomyopathy in the United States.

CAPRNegative Net Change CTMXPositive Net Change SPRONo Net Change CSTLNegative Net Change

Ahan Chakraborty

What Awaits These 4 Biotech Stocks That More Than Doubled in 2024

Here are four drug and biotech stocks, ARQT, MESO, MNPR and KOD, which have more than doubled in 2024 with room for further growth in 2025.

MESONegative Net Change KODPositive Net Change MNPRNo Net Change ARQTNegative Net Change

Zacks Equity Research

TARA Stock Soars on Superior Efficacy of Bladder Cancer Cell Therapy

Protara stock surges 70% as investigational cell therapy, TARA-002, shows superior six-month efficacy in phase II bladder cancer study.

ALNYPositive Net Change PFEPositive Net Change GILDPositive Net Change TARAPositive Net Change